Unknown

Dataset Information

0

A prospective multicenter study of direct comparison of feasibility and safety of pulmonary vein isolation using the minimally interrupted apixaban between second-generation cryoballoon and radiofrequency ablation of paroxysmal atrial fibrillation: J-HIT apixaban.


ABSTRACT: Background:The feasibility and safety of pulmonary vein isolation (PVI) using cryoballoon (CB) for paroxysmal atrial fibrillation (PAF) with minimally interrupted apixaban has not fully explored. Methods:In this multicenter, randomized prospective study, we enrolled patients with PAF undergoing CB or radiofrequency (RF) ablation with interrupted (holding 1 dose) apixaban. The primary composite end point consisted of bleeding events, including pericardial effusion and major bleeding requiring blood transfusion, or thromboembolic events at 4 weeks after ablation; secondary end points included early recurrence of AF and procedural duration. Results:A total of 250 patients underwent PVI (125 assigned to the RF ablation and 125 assigned to the CB ablation). The primary end point occurred in 1 patient in the CB ablation group (0.8%; 90% confidence interval [CI], 0.04 to 3.70) and 3 patients in the RF group (2.4%, P = .622; risk ratio, 0333; 90% CI, 0.05 to 2.20). All events were pericardial effusion, all of whom recovered after pericardiocentesis. Early recurrence of AF occurred in 4 patients (3.2%) in the RF group and in 6 patients (4.8%) in the CB group (P = .749). The procedural duration was shorter in the CB group than that in the RF group (136.5 ± 39.9 vs 179.5 ± 44.8 min, P < .001). Conclusion:CB ablation with minimally interrupted apixaban was feasible and safe in patients with PAF undergoing PVI, which was equivalent to RF ablation.

PROVIDER: S-EPMC7411193 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7544533 | BioStudies
2017-01-01 | S-EPMC5633714 | BioStudies
2016-01-01 | S-EPMC5089471 | BioStudies
2020-01-01 | S-EPMC7004430 | BioStudies
2018-01-01 | S-EPMC6201921 | BioStudies
1000-01-01 | S-EPMC4750134 | BioStudies
2017-01-01 | S-EPMC5445510 | BioStudies
2020-01-01 | S-EPMC7661657 | BioStudies
2015-01-01 | S-EPMC4590523 | BioStudies
2020-01-01 | S-EPMC7171640 | BioStudies